MyFinsight
Home
Compare
Blog
About
Net (decrease)
increase in cash, cash...
-$62,018K
(-157.09%↓ Y/Y)
Proceeds from maturities
of marketable...
$42,586K
Change in fair value of
warrant liabilities
$19,297K
Stock-based compensation
$9,399K
(148.85%↑ Y/Y)
Accounts payable,
accrued liabilities and...
$8,804K
(3278.34%↑ Y/Y)
Prepaid expenses and
other current assets
-$278K
(89.44%↑ Y/Y)
Non-cash lease expense
$109K
(-98.01%↓ Y/Y)
Depreciation expense
$36K
(-98.74%↓ Y/Y)
Proceeds from exercise of
pre-funded warrants
$3K
Net cash (used in)
provided by investing...
-$36,534K
(-8882.21%↓ Y/Y)
Net cash used in
operating activities
-$25,378K
(61.69%↑ Y/Y)
Net cash provided by
financing activities
-$106K
(-100.06%↓ Y/Y)
Canceled cashflow
$42,586K
Canceled cashflow
$37,923K
Canceled cashflow
$3K
Purchases of marketable
securities
$79,000K
Net loss
-$62,807K
(96.09%↑ Y/Y)
Payment of issuance
costs related to...
$107K
(-80.58%↓ Y/Y)
Purchases of property and
equipment
$120K
(-68.67%↓ Y/Y)
Interest amortization on
marketable securities
$425K
(1831.82%↑ Y/Y)
Operating lease
liabilities, net
-$62K
(97.34%↑ Y/Y)
Other assets
$7K
(100.36%↑ Y/Y)
Repurchases of shares for tax
withholdings upon vesting of...
$2K
(-97.70%↓ Y/Y)
Back
Back
Cash Flow
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)
source: myfinsight.com